Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 14 full-time employees. The company went IPO on 2006-12-01. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. The company is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Follow-Up Questions
What is Satellos Bioscience Inc (MSCLF)'s P/E Ratio?
The P/E ratio of Satellos Bioscience Inc is N/A
Who is the CEO of Satellos Bioscience Inc?
Mr. Frank Gleeson is the President of Satellos Bioscience Inc, joining the firm since 2021.
What is the price performance of MSCLF stock?
The current price of MSCLF is 0.4677, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Satellos Bioscience Inc?
Satellos Bioscience Inc belongs to Biotechnology industry and the sector is Health Care
What is Satellos Bioscience Inc market cap?
Satellos Bioscience Inc's current market cap is $82.4
Is Satellos Bioscience Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Satellos Bioscience Inc, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell
